Library / regulatory-reference
Germany: Federal Institute for Drugs and Medical Devices (BfArM)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
BfArM, the Federal Institute for Drugs and Medical Devices, is Germany's federal regulatory authority for medicines and medical devices, operating under the Federal Ministry of Health.
Germany is Europe's largest medicines market, and the institute is responsible for authorization, risk assessment of drugs and devices, and the control of narcotics and precursor substances.
How products enter the market
Medicines require marketing authorization through national or European procedures after evaluation of quality, safety and efficacy, and the institute also oversees the national register for digital health applications.
Post-market work includes pharmacovigilance, device risk assessment and shortage monitoring, with public notices on safety concerns and supply problems.
Regional and international role
The institute is a leading contributor to the European regulatory network and a frequent lead assessor in shared procedures.
Its pairing of drug oversight with a digital-health application pathway makes it a distinctive reference for software-based care regulation.
Using this profile
The authority publishes regulations, registers and alerts in German and English through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: Germany illustrates the federal assessor with a digital pathway: classic drug and device oversight plus a formal route for health apps.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.